CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e265-

  Donner, Aaron J ^a   Yeh, Steve T ^a   Hung, Gene ^a   Graham, Mark J ^a   Crooke, Rosanne M ^a   Mullick, Adam E ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense; CD40; inflammation; kidney

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CD40 ANTIGEN; DOXORUBICIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FRACTIONATION; GLOMERULUS; KIDNEY DISEASE; KIDNEY INTERSTITIUM; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; URETER OBSTRUCTION;

EID: 84948987643     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.40     Document Type: Article

References (42)

1. Coresh, J, Selvin, E, Stevens, LA, Manzi, J, Kusek, JW, Eggers, P et al. (2007). Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047.
2. Moll, S, Meier, M, Formentini, I, Pomposiello, S and Prunotto, M (2014). New renal drug development to face chronic renal disease. Expert Opin Drug Discov 9: 1471-1485.
3. Bohle, A, Mackensen-Haen, S, von Gise, H, Grund, KE, Wehrmann, M, Batz, C et al. (1990). The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 186: 135-144.
4. Grewal, IS and Flavell, RA (1997). The CD40 ligand. At the center of the immune universe? Immunol Res 16: 59-70.
5. Kato, K, Santana-Sahagún, E, Rassenti, LZ, Weisman, MH, Tamura, N, Kobayashi, S et al. (1999). The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104: 947-955.
6. Mach, F (1998). Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394: 200-203.
7. Heeschen, C, Dimmeler, S, Hamm, CW, van den Brand, MJ, Boersma, E, Zeiher, AM et al.; CAPTURE Study Investigators. (2003). Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104-1111.
8. Criswell, LA (2010). Gene discovery in rheumatoid arthritis highlights the CD40/NFkappaB signaling pathway in disease pathogenesis. Immunol Rev 233: 55-61.
9. Suttles, J and Stout, RD (2009). Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 21: 257-264.
10. Danese, S, Sans, M and Fiocchi, C (2004). The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 53: 1035-1043.
11. Ruth, AJ, Kitching, AR, Semple, TJ, Tipping, PG and Holdsworth, SR (2003). Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol 14: 2813-2822.
12. van Kooten, C, Gerritsma, JS, Paape, ME, van Es, LA, Banchereau, J and Daha, MR (1997). Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 51: 711-721.
13. Woltman, AM, de Haij, S, Boonstra, JG, Gobin, SJ, Daha, MR and van Kooten, C (2000). Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 11: 2044-2055.
14. Yellin, MJ, D'Agati, V, Parkinson, G, Han, AS, Szema, A, Baum, D et al. (1997). Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 40: 124-134.
15. Biancone, L, Andres, G, Ahn, H, DeMartino, C and Stamenkovic, I (1995). Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Kidney Int 48: 458-468.
16. Early, GS, Zhao, W and Burns, CM (1996). Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157: 3159-3164.
17. Kalled, SL, Cutler, AH, Datta, SK and Thomas, DW (1998). Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160: 2158-2165.
18. Ripoll, È, Merino, A, Herrero-Fresneda, I, Aran, JM, Goma, M, Bolaños, N et al. (2013). CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms. PLoS One 8: e65068.
19. Ripoll, E, Pluvinet, R, Torras, J, Olivar, R, Vidal, A, Franquesa, M et al. (2011). In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection. Gene Ther 18: 945-952.
20. Kairaitis, L, Wang, Y, Zheng, L, Tay, YC, Wang, Y and Harris, DC (2003). Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 64: 1265-1272.
21. Delville, M, Sigdel, TK, Wei, C, Li, J, Hsieh, SC, Fornoni, A et al. (2014). A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6: 256ra136.
22. Kirk, AD (2009). 4D11: The Second Mouse? Am J Transplant 9: 1701-1702.
23. Sidiropoulos, PI and Boumpas, DT (2004). Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391-397.
24. Okimura, K, Maeta, K, Kobayashi, N, Goto, M, Kano, N, Ishihara, T et al. (2014). Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant 14: 1290-1299.
25. Hung, G, Xiao, X, Peralta, R, Bhattacharjee, G, Murray, S, Norris, D et al. (2013). Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther 23: 369-378.
26. Wang, Y, Wang, YP, Tay, YC and Harris, DC (2000). Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 58: 1797-1804.
27. Lee, VW, Qin, X, Wang, Y, Zheng, G, Wang, Y, Wang, Y et al. (2010). The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis. Nephrol Dial Transplant 25: 717-730.
28. Vowinkel, T, Wood, KC, Stokes, KY, Russell, J, Krieglstein, CF and Granger, DN (2006). Differential expression and regulation of murine CD40 in regional vascular beds. Am J Physiol Heart Circ Physiol 290: H631-H639.
29. Kaissling, B and Le Hir, M (2008). The renal cortical interstitium: morphological and functional aspects. Histochem Cell Biol 130: 247-262.
30. Kitching, AR (2014). Dendritic cells in progressive renal disease: some answers, many questions. Nephrol Dial Transplant 29: 2185-2193.
31. Snelgrove, SL, Kausman, JY, Lo, C, Lo, C, Ooi, JD, Coates, PT et al. (2012). Renal dendritic cells adopt a pro-inflammatory phenotype in obstructive uropathy to activate T cells but do not directly contribute to fibrosis. Am J Pathol 180: 91-103.
32. Pluvinet, R, Olivar, R, Krupinski, J, Herrero-Fresneda, I, Luque, A, Torras, J et al. (2008). CD40: an upstream master switch for endothelial cell activation uncovered by RNAicoupled transcriptional profiling. Blood 112: 3624-3637.
33. El Fakhry, Y, Alturaihi, H, Yacoub, D, Liu, L, Guo, W, Leveillé, C et al. (2012). Functional interaction of CD154 protein with 5 1 integrin is totally independent from its binding to IIb 3 integrin and CD40 molecules. J Biol Chem 287: 18055-18066.
34. Okwor, I, Jia, P and Uzonna, JE (2015). Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major. J Immunol 195: 3218-3226.
35. Wolf, D, Hohmann, JD, Wiedemann, A, Bledzka, K, Blankenbach, H, Marchini, T et al. (2011). Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice. Circ Res 109: 1269-1279.
36. Nathan, MJ, Mold, JE, Wood, SC, Csencsits, K, Lu, G, Eichwald, EJ et al. (2004). Requirement for donor and recipient CD40 expression in cardiac allograft rejection: induction of Th1 responses and influence of donor-derived dendritic cells. J Immunol 172: 6626-6633.
37. Geary, RS (2009). Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5: 381-391.
38. Seth, PP, Siwkowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2009). Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52: 10-13.
39. Harris, RH and Gill, JM (1981). Changes in glomerular filtration rate during complete ureteral obstruction in rats. Kidney Int 19: 603-608.
40. Seth, PP, Siwkowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2008). Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symposium Series 52: 553-554.
41. Takemoto, M, Asker, N, Gerhardt, H, Lundkvist, A, Johansson, BR, Saito, Y et al. (2002). A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805.
42. Qi, Z, Whitt, I, Mehta, A, Jin, J, Zhao, M, Harris, RC et al. (2004). Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596.